Anson Funds Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Anson Funds Management’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-105,685	Closed	-$45.4K	–	123
2025 Q1	$45.4K	Buy	105,685 +101,048	+2,179%	+$985K	0.01%	115
2024 Q4	$89.9K	Hold	4,637	–	–	0.01%	140
2024 Q3	$128K	Buy	+4,637	New	+$184K	0.01%	143
2018 Q1	–	Sell	-2	Closed	-$446K	–	39
2017 Q4	$446K	Buy	+2	New	+$569K	0.3%	33
2017 Q3	–	Sell	-4	Closed	-$1.39M	–	57
2017 Q2	$1.39M	Buy	+4	New	+$1.99M	0.44%	30
2016 Q2	–	Sell	-2	Closed	-$1.37M	–	63
2016 Q1	$1.37M	Buy	+2	New	+$1.23M	0.2%	41

Other funds holding HEPA

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Anson Funds Management's HEPA Position: Q2 2025 in Review

Anson Funds Management sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 105,685 shares — an estimated $45.4K sold.

Anson Funds Management first reported a position in HEPA in Q1 2016 and held it in 6 quarters. The position peaked at $1.39M in Q2 2017. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.

Anson Funds Management reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Anson Funds Management sold 105,685 Hepion Pharmaceuticals shares in Q2 2025, an estimated $45.4K.
Anson Funds Management first reported a position in Hepion Pharmaceuticals in Q1 2016 and held it in 6 quarters.
Anson Funds Management's Hepion Pharmaceuticals position peaked at $1.39M in Q2 2017.
4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.

Based on Anson Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.